Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Trading 03-28 12:09:54 EDT

155.66

-2.28

-1.44%

High158.55	Low154.15	Vol88.32K
Open157.94	D1 Closing157.94	Amplitude2.78%
Mkt Cap9.32B	Tradable Cap9.24B	Total Shares59.84M
T/O13.74M	T/O Rate0.15%	Tradable Shares59.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":155.66,"timestamp":1743178173100,"preClose":157.94,"halted":0,"volume":88318,"delay":0,"floatShares":59372559,"shares":59843600,"eps":-6.761465,"marketStatus":"Trading","change":-2.28,"latestTime":"03-28 12:09:54 EDT","open":157.94,"high":158.545,"low":154.15,"amount":13736367.02672,"amplitude":0.027827,"askPrice":155.8,"askSize":7,"bidPrice":155.42,"bidSize":14,"shortable":3,"etf":0,"ttmEps":-6.761465,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":157.94,"preHourTrading":{"tag":"盘前","latestPrice":158.94,"preClose":157.94,"latestTime":"08:44 EDT","volume":404,"amount":63952.117280000006,"timestamp":1743165852314},"postHourTrading":{"tag":"盘后","latestPrice":157.94,"preClose":157.94,"latestTime":"19:52 EDT","volume":5813,"amount":918263.83,"timestamp":1743119546136},"volumeRatio":0.66548,"impliedVol":0.4378,"impliedVolPercentile":0.372},"requestUrl":"/m/hq/s/ASND","defaultTab":"news","newsList":[{"id":"2522006169","title":"European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006169","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006169?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:08","pubTimestamp":1742915311,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were higher late Tuesday morning, up 0.73% to 1,435.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","LU0320765992.SGD","LU2129689431.USD","BK4107","BK4117","BK4585","BK7505","LU2236285917.USD","EDAP","BK4548","LU2129689605.HKD","LU0648005311.SGD","NTZ","LU2237443382.USD","NCNA","AKTX","BK4207","BK4535","EVAX","LU2237443895.HKD","LU2129689514.USD","LU1162221912.USD","LU2237443465.HKD","TTE","BK4139","BK4134","ING","DAVA.AU","ASND","BK4201","AFG","BK4551","LU0084288595.USD","ADAP","DBVT","BK4007","SLN","LU2237443978.SGD","BNTX","BDRX","MREO","ING.AU","LU0300736062.USD","BK7141","LU0098860793.USD","LU2237443549.SGD","DAVA","LU0300736492.USD","SHEL","LU0889565916.HKD"],"gpt_icon":0},{"id":"2520813070","title":"European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2520813070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520813070?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 23:03","pubTimestamp":1742396608,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Wednesday morning, declining 0.36% to 1,442.32 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor company Sequans Communications  and internet browser company Opera , which rose 3.6% each. They were followed by 3D printer company Materialise  and petroleum refiner Equinor , which were up 2.2% and 1.9% respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and financial services company Banco Bilbao Vizcaya Argentaria , which fell 2.5% and 2.1% respectively. They were followed by pharmaceutical companies Ascendis Pharma  and Novo Nordisk , which were down 1.8% and 1.3% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals  and Akari Therapeutics , which advanced 25% and 5% respectively. They were followed by biopharmaceutical company Amarin  and cru","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASND","BK4585","LU1093756168.USD","EQNR","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4599","LU1829250122.USD","NCNA","AFG","BK4201","BK4139","BK4007","BK4023","BK4546","LU1093756325.SGD","LU0320765992.SGD","BK4117","TRIB","AKTX","DBVT","BK4141","LU0154236417.USD","OPRA","BK4532","BK4142","SQNS","IE00BKVL7J92.USD","LU0109394709.USD","GSK.UK","BK4107","BK4082","NVO.AU","BK7104","BBVA","BK4588","CUK","SNN","AMRN","BK4207","MTLS","BDRX","GSK"],"gpt_icon":1},{"id":"2520675446","title":"Ascendis Pharma Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2520675446","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520675446?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:38","pubTimestamp":1742301480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 08:38 ET (12:38 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"gpt_icon":0},{"id":"2520757405","title":"European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2520757405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520757405?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 23:00","pubTimestamp":1742223615,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, rising 1.12% to 1,433.84 on the S&P Europe Select ADR Index.From continental Europe, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASND","BK4585","LU1093756168.USD","BK4077","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4599","EDAP","BK4162","AFG","DAVA","VRNA","BK4139","BK4007","BCYC","BK4134","LU1093756325.SGD","BK4117","TRIB","AKTX","DBVT","BK4141","LU0154236417.USD","BK4532","IE00BFMHRM44.USD","PUK","DAVA.AU","BK4142","SQNS","CLLS","IE00BKVL7J92.USD","LU0109394709.USD","NVO","BK4107","LU0084288595.USD","BK4009","BK4082","NVO.AU","BK7104","BK4588","TRVG","CUK","CRTO","LU0648005311.SGD","AMRN","LU0320765992.SGD"],"gpt_icon":1},{"id":"2519855800","title":"European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2519855800","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519855800?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:09","pubTimestamp":1741878554,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were treading water late Thursday morning, edging 0.1% higher to 1,396.7 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS  and pharmaceutical company Novo Nordisk , which rose 4.7% and 3.3% respectively. They were followed by pharmaceutical company Ascendis Pharma  and telecommunications operator Telefonica , which were up 1.7% and 1.5% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications  and software firm SAP , which fell 2.7% and 2.3% respectively. They were followed by biotechnology companies argenx  and Evaxion Biotech , which dropped 2.1% and 0.9% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics  and telecommunications operator Vodafone Group , which increased 5.2% and 3% respectively. They were followed by pharmaceutical companies Amari","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASND","BK4585","AZN","EVAX","LU1093756168.USD","LU2456880835.USD","IE00BZ1G4Q59.USD","BK4505","LU0889565916.HKD","BK4599","EDAP","LU1829250122.USD","NCNA","BK4115","AFG","BK4139","BK4007","TEF","BK4023","LU2462157665.USD","LU1093756325.SGD","LU2236285917.USD","LU0320765992.SGD","BK4117","AKTX","BK4141","LU0154236417.USD","BK4532","BK4613","SQNS","ARGX","IE00BKVL7J92.USD","LU0109394709.USD","BCS","TCBP","LU2417539215.USD","NVO","BK4107","VOD","SAP","BK4132","NVO.AU","BK7104","BK4588","AMRN","BK4207","BK4528","BK4568","SLN","BK4521"],"gpt_icon":1},{"id":"2517430667","title":"European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430667","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517430667?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 00:14","pubTimestamp":1741364099,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending higher late Friday morning, rising 0.62% to 1,443.18 on the S&P Europe Select ADR Index, which is up 0.36% for the week","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUK","BK4009","ARGX","BK4011","AKTX","LU0154236417.USD","LU2298321311.HKD","AFG","EDAP","LU0238689110.USD","IE00BFMHRM44.USD","BDRX","BK4599","BK4588","LU0868494708.USD","BK4142","BK4132","CLLS","LU1863844665.USD","LU1880398554.USD","EQNR","LU1506573853.SGD","LU0128525929.USD","LU0029864427.USD","LU0889565916.HKD","LU0310800379.SGD","ARBK","OPRA","VOD","LU1267930573.SGD","LU0109394709.USD","LU1019634622.SGD","CRH","CRTO","NVO.AU","BK4007","SLN","ASND","BK4082","LU1093756325.SGD","LU1880398471.USD","BK7104","LU2041044095.USD","BK4117","BK4139","AUTL","LU1291149836.SGD","IE00BZ1G4Q59.USD","BK4107"],"gpt_icon":1},{"id":"2517791120","title":"TD Cowen Sticks to Its Buy Rating for Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517791120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517791120?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:17","pubTimestamp":1741180677,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-its-buy-rating-for-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND","TD","COWN"],"gpt_icon":0},{"id":"2516656750","title":"Exploring US High Growth Tech Stocks In March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656750","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656750?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 01:08","pubTimestamp":1741021696,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a slight decline of 1.3%, yet it has shown resilience with a 15% increase over the past year and earnings forecast to grow by 14% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to sustain growth amidst fluctuating market conditions.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener.Overview: Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases, with a market cap of $2.23 billion.Operations: Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases. As a clinical-stage biopharmaceutical company, it is currently not generating revenue from its operations.Dive into ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-us-high-growth-tech-170816186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1153585028.USD","LU2125909247.SGD","LU1917777945.USD","LU1323610961.USD","LU0354030438.USD","LU0320765992.SGD","LU1923622291.USD","LU0109391861.USD","LU0672654240.SGD","LU0109392836.USD","LU2286300806.USD","LU0708995401.HKD","LU0265550946.USD","LU0353189680.USD","LU0689472784.USD","BK4608","BK4566","LU0943347566.SGD","IE00B19Z9P08.USD","LU0082616367.USD","LU1803068979.SGD","LU0354030511.USD","LU2125909593.SGD","LU1923623000.USD","LU1064131342.USD","LU0820561909.HKD","LU2023250504.SGD","SLNO","ASND","IE00BZ9MQY76.HKD","LU2458330169.SGD","LU0316494557.USD","LU2125909916.SGD","LU0889565916.HKD","LU1989764664.SGD","LU2125909759.SGD","BK4534","LU2458330243.SGD","NOW","LU0719512351.SGD","LU0353189763.USD","LU0348723411.USD","LU0320765059.SGD","LU1116320737.USD","LU0011850046.USD","BK4607","LU2023250843.SGD","BK4097","LU1988902786.USD","LU2106854487.HKD","LU1989772923.USD"],"gpt_icon":0},{"id":"2516263301","title":"Ascendis Pharma (ASND) Receives a Hold from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2516263301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516263301?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:06","pubTimestamp":1741007215,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-hold-from-morgan-stanley-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-hold-from-morgan-stanley-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4516","LU0795875086.SGD","LU1162221912.USD","LU2028103732.USD","LU1074936037.SGD","LU2357305700.SGD","LU0109394709.USD","LU1989772923.USD","LU2089284900.SGD","LU2271345857.HKD","LU0106831901.USD","IE00BZ1G4Q59.USD","BK4585","LU1720051108.HKD","LU0106261372.USD","LU0158827948.USD","LU1732800096.USD","LU0971096721.USD","LU2133065610.SGD","LU0795875169.SGD","BK4504","ASND","IE00BKVL7J92.USD","LU1363072403.SGD","LU1668664300.SGD","LU1720051017.SGD","LU2347655156.SGD","LU0320765646.SGD","LU0225283273.USD","BK4139","LU1989772840.SGD","LU2111349929.HKD","LU0889565916.HKD","LU0320765992.SGD","LU0314104364.USD","LU1732799900.SGD","LU0158827781.USD","LU0006306889.USD","LU2023251221.USD","LU1548497426.USD","LU0912757837.SGD","BK4581","BK4534","LU2089283258.USD","LU0267386448.USD","BK4588","LU0098860793.USD","BK4127"],"gpt_icon":0},{"id":"2514097594","title":"Ascendis Pharma Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514097594?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 22:26","pubTimestamp":1740493560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 09:26 ET (14:26 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"gpt_icon":0},{"id":"2513729580","title":"Morgan Stanley Sticks to Their Hold Rating for Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729580?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:18","pubTimestamp":1740403127,"startTime":"0","endTime":"0","summary":"In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-hold-rating-for-ascendis-pharma-asnd-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-hold-rating-for-ascendis-pharma-asnd-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND"],"gpt_icon":0},{"id":"2512017280","title":"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Medtronic (MDT) and Tyra Bioscience (TYRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512017280","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512017280?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 18:02","pubTimestamp":1739959343,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Medtronic ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-medtronic-mdt-and-tyra-bioscience-tyra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-medtronic-mdt-and-tyra-bioscience-tyra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0496365809.HKD","LU1983299246.USD","IE00B3T34201.USD","LU0265550359.USD","LU1291159041.SGD","LU2023251221.USD","TYRA","LU2089283258.USD","LU0208291251.USD","IE00BQXX3D17.EUR","LU0320765992.SGD","BK4533","LU1571399168.USD","BK4585","LU0320765489.SGD","LU0158827781.USD","IE00BFXG1179.USD","BK4082","LU1989764664.SGD","IE00BQXX3C00.GBP","LU2111349929.HKD","LU0162691827.USD","LU2468319806.SGD","LU0109394709.USD","ASND","LU0072461881.USD","LU1116320737.USD","MDT","LU2271345857.HKD","LU0211326839.USD","BK4588","BK4566","LU2028103732.USD","LU0211331839.USD","LU0265550946.USD","IE00BQXX3F31.USD","LU0070302665.USD","LU0158827948.USD","LU2089984988.USD","LU1116320901.HKD","BK4137","IE000M9KFDE8.USD","LU0976567544.SGD","LU1989771016.USD","LU0211326755.USD","LU2089284900.SGD","LU1989764748.USD","LU0889565916.HKD","HCSG"],"gpt_icon":0},{"id":"2512164436","title":"European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2512164436","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512164436?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 00:03","pubTimestamp":1739894589,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were sharply higher late Tuesday morning, rising 1.18% to 1,408.93 on the S&P Europe Select ADR Index.From continental Europe, the ga","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AFG","BK4599","BK4142","BBVA","BK4007","BK4207","HSBA.UK","IE00BZ1G4Q59.USD","EDAP","BCS","IHG","NVO","BK1231","LU0310800965.SGD","LU0516423091.SGD","BK4585","DAVA","BK7104","LU0109394709.USD","LU0648005311.SGD","IE00BKVL7J92.USD","AKTX","BK4201","DAVA.AU","GRFS","DBVT","NVO.AU","ASND","HSBC","LU1267930227.SGD","LU0540923850.HKD","LU0084288595.USD","BK1610","BK1601","03143","EQNR","LU1093756325.SGD","LU0128525689.USD","BK4107","VRNA","LU0164880469.USD","SLN","BK4521","00005","LU0154236417.USD","ADAP","HSHD.SI","GNFT","LU0516423174.USD","BK4117"],"gpt_icon":1},{"id":"2512016120","title":"Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2512016120","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512016120?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 23:38","pubTimestamp":1739893080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 10:38 ET (15:38 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"gpt_icon":0},{"id":"2511796671","title":"Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511796671","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511796671?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 20:38","pubTimestamp":1739623126,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S  defied analyst predictions to release its annual results, which were ahead of market expectations. The overall earnings picture was okay, with revenues of 364m beating expectations by 13%. Statutory losses were 6.53 per share, only marginally better than what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascendis-pharma-nasdaq-asnd-just-123846036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","ASND","NDAQ"],"gpt_icon":0},{"id":"2511666757","title":"Ascendis Pharma Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2511666757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511666757?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 18:59","pubTimestamp":1739530741,"startTime":"0","endTime":"0","summary":"NasdaqGS:ASND Revenue and Expenses Breakdown February 14th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 13%. Earnings per share  also surpassed analyst estimates by 4.4%.The primary driver behind last 12 months revenue was the North America segment contributing a total revenue of 233.2m . The largest operating expense was Research & Development (R&D) costs, amounting to 307.0m . Explore how ASND's revenue and expenses shape its earnings.Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are up 14% from a week ago.Every company has them, and we've spotted   1 warning sign for Ascendis Pharma   you should know about.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascendis-pharma-full-2024-earnings-105901763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASND"],"gpt_icon":0},{"id":"2511636078","title":"Evercore ISI Remains a Buy on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2511636078","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511636078?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 14:06","pubTimestamp":1739513203,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-ascendis-pharma-asnd-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-ascendis-pharma-asnd-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND","LU0889565916.HKD","BK4585","LU0109394709.USD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2511635435","title":"Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2511635435","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511635435?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 13:00","pubTimestamp":1739509223,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Ascendis Pharma AS  achieved significant milestones in 2024, setting the stage for strong growth and value creation.Skytrofa has established itself as a high-value growth hormone brand, capturing a 6.5% market share in the US.Transcon PTH, the only FDA-approved treatment for hypoparathyroidism in adults, has launched in the US and is gaining traction as a new standard of care.The company has a strong financial position with cash equivalents totaling 665 million, including a 100 million upfront payment from Novo Nordisk.Revenue for Skytrofa in Q4 2024 was lower than the same period in 2023, despite volume growth.The company faces challenges in establishing insurance reimbursement policies for new products like Yorvipa.There is uncertainty regarding the timeline for insurance approvals, which are estimated to take 4 to 8 weeks.Operating expenses increased by 3% in Q4 2024 compared to the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascendis-pharma-asnd-q4-2024-050023167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASND"],"gpt_icon":0},{"id":"2511009935","title":"Ascendis Pharma A/S Earnings Call Highlights Growth and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2511009935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511009935?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 08:51","pubTimestamp":1739494260,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (($ASND)) has held its Q4 earnings call. Read on for the main highlights of the call. Ascendis Pharma A/S’s latest earnings cal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-earnings-call-highlights-growth-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-earnings-call-highlights-growth-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASND"],"gpt_icon":0},{"id":"2511716815","title":"Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511716815","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511716815?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 03:40","pubTimestamp":1739475630,"startTime":"0","endTime":"0","summary":"Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath&#39;s EU launch. Goldman Sachs raised its price target.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/02/43708807/why-is-rare-disease-focused-ascendis-pharma-stock-trading-higher-on-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU2237443465.HKD","LU2237443895.HKD","LU2237443978.SGD","TQQQ","LU0154236417.USD","BMRN","LU1791807156.HKD",".IXIC","LU0106831901.USD","ASND","NVIW.SI","LU2750360997.AUD","IE0004086264.USD","BK4504","IE00B19Z3581.USD","USAW.SI","AZN","QLD","LU2237443382.USD","LU2471134796.USD","QID","LU2471134523.USD","IE00BKVL7J92.USD","LU2417539215.USD","BK4552","IE0004091025.USD","SQQQ","PSQ","BK4599","BK4127","NVO","BK4588","MNQmain","TSYW.SI","IE00B7SZLL34.SGD","BK4585","NQmain","IE00BSNM7G36.USD","LU1668664300.SGD","LU2462157665.USD","BK4566","LU1829250122.USD","USJW.SI","BK4007","LU2237438978.USD","BK4568","BK4516","BK4550"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":-0.0325},{"period":"1month","weight":0.0423},{"period":"3month","weight":0.1487},{"period":"6month","weight":0.0921},{"period":"1year","weight":0.064},{"period":"ytd","weight":0.1472}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.028378},{"month":2,"riseRate":0.545455,"avgChangeRate":0.052339},{"month":3,"riseRate":0.545455,"avgChangeRate":0.036279},{"month":4,"riseRate":0.3,"avgChangeRate":-0.046884},{"month":5,"riseRate":0.4,"avgChangeRate":0.000611},{"month":6,"riseRate":0.6,"avgChangeRate":0.017012},{"month":7,"riseRate":0.6,"avgChangeRate":-0.000153},{"month":8,"riseRate":0.7,"avgChangeRate":0.081464},{"month":9,"riseRate":0.6,"avgChangeRate":0.041437},{"month":10,"riseRate":0.4,"avgChangeRate":-0.012194},{"month":11,"riseRate":0.8,"avgChangeRate":0.046776},{"month":12,"riseRate":0.5,"avgChangeRate":0.04575}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction